| Issue Date | Title | Author(s) |
| 2022 | EFFICACY AND SAFETY OF CM310 IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN CHINA | Zhang, Jianzhong; Yang, Bin; Li, Jingyi; Ding, Yangfeng; Wu, Liming; Zhang, Litao; Wang, Jinyan; Zhu, Xiaohong; Zhang, Furen; Tao, Xiaohua; Li, Yumei; Zhang, Chunlei; Li, Linfeng; Lu, Jianyun; Diao, Qingchun; Lu, Qianjin; Man, Xiaoyong; Li, Fuqiu; Xia, Xiujuan; Cheng, Hao; Zhao, Yan; Chen, Bo; Yan, Jinchun; Zhao, Guoqing; Jia, Yingmin |
| 15-May-2024 | Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis | Ma, Lin; Tao, Xiaohua; Liu, Sujun; Cheng, Hao; Fang, Ruihua; Zhao, Yan; Cha, Amy; Encinas, Gerardo A.; Zhou, Yangmei; Deng, Yujie; Zhang, Jianzhong |
| Aug-2021 | Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial | Zhao, Yan; Zhang, Litao; Ding, Yangfeng; Tao, Xiaohua; Ji, Chao; Dong, Xiuqin; Lu, Jianyun; Wu, Liming; Wang, Rupeng; Lu, Qianjin; Goh, Aik Han; Liu, Rongjun; Zhang, Zhiguo; Zhang, Jianzhong |
| 25-Oct-2024 | Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial | Zhao, Yan; Zhang, Litao; Wu, Liming; Yang, Bin; Wang, Jinyan; Li, Yumei; Li, Jingyi; Diao, Qingchun; Sun, Qing; Zhu, Xiaohong; Man, Xiaoyong; Wang, Lihua; Li, Linfeng; Feng, Yanyan; Zeng, Huiming; Cai, Tao; Ren, Hong; Lu, Jianyun; Lu, Qianjin; Tao, Xiaohua; Xiao, Rong; Ji, Chao; Li, Fuqiu; Zhang, Jianzhong |
